profile_id,first_name,last_name,sub_title,profile_picture,background_image,profile_type,entity_urn,object_urn,birth_date,summary,location,premium,influencer,treasury_media,languages,industry,education,patents,awards,certifications,organizations,projects,publications,courses,test_scores,position_groups,volunteer_experiences,skills,network_info,related_profiles,contact_info
joost-uitdehaag-3645665,Joost,Uitdehaag,Head of Biology,https://media.licdn.com/dms/image/C4D03AQGEpAg90R-ZWw/profile-displayphoto-shrink_800_800/0/1635883556631?e=1697673600&v=beta&t=abhE41z7v0EpxqWAHHUAQWlAlDE6mya_nhjQjVjzXEM,https://media.licdn.com/dms/image/C5616AQHBBhhbT6rC4g/profile-displaybackgroundimage-shrink_350_1400/0/1636876292547?e=1697673600&v=beta&t=zPJdOEatMJueClcEekMdl_AXYnnBXeWXJ7Mj1vh7Xhc,personal,ACoAAAD43HwBOHaT9Au23QTTZ6lggeN58e90U44,16309372,,"An accomplished expert in drug discovery with a passion for oncology. Currently I am Head of Biology at NTRC Therapeutics, where I work with my team on a new generation of tailored kinase inhibitors. Previously  as Associate Director at AstraZeneca  I chaired the transatlantic committee for scouting and validating new targets in hematology oncology. As director program management at LAVA Therapeutics N.V., I brought LAVA-1207, a bispecific T-cell engager for prostate cancer past CTA and IND and into clinical phase I/II, and managed a collaboration with Janssen Pharma. In 2011, I co-started the biotech company NTRC, which developed the TTK inhibitor BAL-0891, currently in clinical phase. Before that, had roles at Organon N.V. and MSD.
I have been working in drug discovery since 2003 during which I transformed preclinical concepts into more than a dozen clinical candidates, and had an insider's perspective on the discovery and development of the marketed drugs acalabrutinib and pembrolizumab. Author of >130 publications, h-index 31. Let's make drug discovery happen.","{'country': None, 'short': 'Netherlands', 'city': None, 'state': None, 'default': 'Netherlands'}",False,False,"[{'url': 'https://mct.aacrjournals.org/content/18/2/470', 'title': 'Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017', 'description': 'Kinase inhibitors form the largest class of precision medicine. From 2013 to 2017, 17 have been approved, with 8 different mechanisms. We present a comprehensive profiling study of all 17 inhibitors on a biochemical assay panel of 280 kinases and...', 'image': 'https://media.licdn.com/dms/image/sync/C4E27AQG522dO7lrV8Q/articleshare-shrink_800/0/1566661166935?e=1692964800&v=beta&t=BENqdHxdJBWIvMY5JYy-QV3o-LpcGzFKhAO93-9KeTc'}]","{'primary_locale': {'country': 'US', 'language': 'en'}, 'supported_locales': [{'country': 'US', 'language': 'en'}], 'profile_languages': [{'name': 'Dutch', 'proficiency': None}, {'name': 'English', 'proficiency': None}, {'name': 'French', 'proficiency': None}, {'name': 'German', 'proficiency': None}]}",Pharmaceuticals,"[{'date': {'start': {'month': None, 'day': None, 'year': 1995}, 'end': {'month': None, 'day': None, 'year': 2000}}, 'school': {'name': 'University of Groningen', 'logo': 'https://media.licdn.com/dms/image/C560BAQHjFD1KsBlUnQ/company-logo_400_400/0/1519868080428?e=1700697600&v=beta&t=d2tRvbRlXMKelxD8kEz9CA-lmIOif13yVqBXFWP5Jc4', 'url': 'https://www.linkedin.com/school/rijksuniversiteit-groningen/'}, 'degree_name': 'Ph.D.', 'field_of_study': 'mathematics and physics, protein crystallography'}, {'date': {'start': {'month': None, 'day': None, 'year': 1994}, 'end': {'month': None, 'day': None, 'year': 1995}}, 'school': {'name': 'University of Oxford', 'logo': 'https://media.licdn.com/dms/image/C560BAQGwPZs3spXFqw/company-logo_400_400/0/1539693367639?e=1700697600&v=beta&t=fIuLWhoOjqusT3q-nMhbr76n-POJcsxAGZrC91Cq38M', 'url': 'https://www.linkedin.com/school/oxforduni/'}, 'degree_name': 'undergraduate', 'field_of_study': 'Biochemistry'}, {'date': {'start': {'month': None, 'day': None, 'year': 1989}, 'end': {'month': None, 'day': None, 'year': 1995}}, 'school': {'name': 'Wageningen University & Research', 'logo': 'https://media.licdn.com/dms/image/C510BAQFQJQXtOy2Stw/company-logo_400_400/0/1519889640020?e=1700697600&v=beta&t=DfM4gdRk76TMhZBoa5gWFhnkNZBuUm47LktavPNU9gg', 'url': 'https://www.linkedin.com/school/wageningenuniversity/'}, 'degree_name': 'Master of Science', 'field_of_study': 'Molecular Sciences'}]",[],[],"[{'name': 'stralingsdeskunde niveau 5B (working with radiation)', 'date': {'start': {'month': 3, 'day': None, 'year': 2004}, 'end': {'month': None, 'day': None, 'year': None}}, 'authority': 'Radboud University', 'url': None, 'license_number': None, 'display_source': None, 'company': {'id': None, 'name': 'Radboud University', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQHgdni-2v0psQ/company-logo_400_400/0/1670846116863?e=1700697600&v=beta&t=vgJeC3CA6j7MZM594LPJ9niyV2uONRQXRNwcseFWVLI', 'url': None}}]","[{'name': 'The Antibody Society', 'position': 'member', 'date_start': {'month': 3, 'day': None, 'year': 2020}, 'date_end': None}, {'name': 'American Association for Cancer Research', 'position': 'active member', 'date_start': {'month': 10, 'day': None, 'year': 2015}, 'date_end': None}, {'name': 'European Association for Cancer Research', 'position': None, 'date_start': {'month': 9, 'day': None, 'year': 2013}, 'date_end': None}]",[],"[{'name': 'Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017', 'publisher': 'Molecular Cancer Therapeutics', 'url': 'https://mct.aacrjournals.org/content/early/2018/10/31/1535-7163.MCT-18-0877', 'date': {'month': None, 'day': None, 'year': 2019}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Jeffrey', 'last_name': 'Kooijman', 'name': None, 'headline': 'Senior Scientist at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Jeroen', 'last_name': 'de Roos', 'name': None, 'headline': 'Sr Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Jelle', 'last_name': 'Dylus', 'name': None, 'headline': 'Scientist Biology at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Martine', 'last_name': 'Prinsen', 'name': None, 'headline': 'Senior Scientist Biology at NTRC Therapeutics B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Nicole', 'last_name': 'Willemsen-Seegers', 'name': None, 'headline': 'Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Jos', 'last_name': 'de Man', 'name': None, 'headline': 'Senior Investigator at NTRC Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Suzanne', 'last_name': 'van Gerwen', 'name': None, 'headline': 'Director Business Development Early Access Programs'}, {'type': 'standardizedContributor', 'first_name': 'Rogier', 'last_name': 'Buijsman', 'name': None, 'headline': 'Managing Director at NTRC Therapeutics BV'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}]}, {'name': 'TTK Inhibitors as a Targeted Therapy for CTNNB1 (Î²-catenin) Mutant Cancers.', 'publisher': 'Molecular Cancer Therapeutics', 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/28751540', 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Jeroen', 'last_name': 'de Roos', 'name': None, 'headline': 'Sr Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Marion', 'last_name': 'Libouban, PhD', 'name': None, 'headline': 'Associate Director, Translational Medicine Lead at iTeos Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Martine', 'last_name': 'Prinsen', 'name': None, 'headline': 'Senior Scientist Biology at NTRC Therapeutics B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Jos', 'last_name': 'de Man', 'name': None, 'headline': 'Senior Investigator at NTRC Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Rogier', 'last_name': 'Buijsman', 'name': None, 'headline': 'Managing Director at NTRC Therapeutics BV'}]}, {'name': 'Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity.', 'publisher': 'Journal of Molecular Biology', 'url': 'https://www.ncbi.nlm.nih.gov/pubmed/28539250', 'date': {'month': None, 'day': None, 'year': 2017}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Jos', 'last_name': 'de Man', 'name': None, 'headline': 'Senior Investigator at NTRC Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Nicole', 'last_name': 'Willemsen-Seegers', 'name': None, 'headline': 'Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Martine', 'last_name': 'Prinsen', 'name': None, 'headline': 'Senior Scientist Biology at NTRC Therapeutics B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Marion', 'last_name': 'Libouban, PhD', 'name': None, 'headline': 'Associate Director, Translational Medicine Lead at iTeos Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Jan Gerard', 'last_name': 'Sterrenburg', 'name': None, 'headline': 'Senior Scientist Chemistry at NTRC Therapeutics B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Joeri', 'last_name': 'de Wit', 'name': None, 'headline': 'Senior Scientist Chemistry at NTRC Therapeutics BV'}, {'type': 'standardizedContributor', 'first_name': 'Judith', 'last_name': 'de Vetter', 'name': None, 'headline': 'Technisch onderwijs assistent op Avans Hogeschool'}, {'type': 'standardizedContributor', 'first_name': 'Jeroen', 'last_name': 'de Roos', 'name': None, 'headline': 'Sr Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Rogier', 'last_name': 'Buijsman', 'name': None, 'headline': 'Managing Director at NTRC Therapeutics BV'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}]}, {'name': 'Cell panel profiling reveals conserved therapeutic clusters and differentiates the mechanism of action of different PI3K/mTOR, Aurora kinase and EZH2 inhibitors', 'publisher': 'Molecular Cancer Therapeutics', 'url': 'http://mct.aacrjournals.org/content/early/2016/09/01/1535-7163.MCT-16-0403', 'date': {'month': None, 'day': None, 'year': 2016}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Jeroen', 'last_name': 'de Roos', 'name': None, 'headline': 'Sr Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Martine', 'last_name': 'Prinsen', 'name': None, 'headline': 'Senior Scientist Biology at NTRC Therapeutics B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Nicole', 'last_name': 'Willemsen-Seegers', 'name': None, 'headline': 'Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Judith', 'last_name': 'de Vetter', 'name': None, 'headline': 'Technisch onderwijs assistent op Avans Hogeschool'}, {'type': 'standardizedContributor', 'first_name': 'Jelle', 'last_name': 'Dylus', 'name': None, 'headline': 'Scientist Biology at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Suzanne', 'last_name': 'van Gerwen', 'name': None, 'headline': 'Director Business Development Early Access Programs'}, {'type': 'standardizedContributor', 'first_name': 'Jos', 'last_name': 'de Man', 'name': None, 'headline': 'Senior Investigator at NTRC Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Rogier', 'last_name': 'Buijsman', 'name': None, 'headline': 'Managing Director at NTRC Therapeutics BV'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}]}, {'name': 'Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs', 'publisher': 'PLOS ONE', 'url': 'http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125021', 'date': {'month': None, 'day': None, 'year': 2015}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Jeroen', 'last_name': 'de Roos', 'name': None, 'headline': 'Sr Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Antoon', 'last_name': 'van Doornmalen', 'name': None, 'headline': 'Retired Senior Scientist'}, {'type': 'standardizedContributor', 'first_name': 'Martine', 'last_name': 'Prinsen', 'name': None, 'headline': 'Senior Scientist Biology at NTRC Therapeutics B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Jill', 'last_name': 'Spijkers-Hagelstein', 'name': None, 'headline': 'Freelance Medical Affairs Consultant'}, {'type': 'standardizedContributor', 'first_name': 'Judith', 'last_name': 'de Vetter', 'name': None, 'headline': 'Technisch onderwijs assistent op Avans Hogeschool'}, {'type': 'standardizedContributor', 'first_name': 'Jos', 'last_name': 'de Man', 'name': None, 'headline': 'Senior Investigator at NTRC Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Rogier', 'last_name': 'Buijsman', 'name': None, 'headline': 'Managing Director at NTRC Therapeutics BV'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}]}, {'name': 'Comparison of the Cancer Gene Targeting and Biochemical Selectivities of All Targeted Kinase Inhibitors Approved for Clinical Use', 'publisher': 'PLOS ONE', 'url': 'http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0092146', 'date': {'month': None, 'day': None, 'year': 2014}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Jeroen', 'last_name': 'de Roos', 'name': None, 'headline': 'Sr Investigator at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Antoon', 'last_name': 'van Doornmalen', 'name': None, 'headline': 'Retired Senior Scientist'}, {'type': 'standardizedContributor', 'first_name': 'Martine', 'last_name': 'Prinsen', 'name': None, 'headline': 'Senior Scientist Biology at NTRC Therapeutics B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Jos', 'last_name': 'de Man', 'name': None, 'headline': 'Senior Investigator at NTRC Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Yoshinori', 'last_name': 'Tanizawa', 'name': None, 'headline': 'Health Outcome Scientist - Japan Value, Evidence and Outcomes at Eli Lilly Japan'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Yusuke Kawase', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Kohichiro', 'last_name': 'Yoshino', 'name': None, 'headline': 'President & CEO - Carna Biosciences, Inc.'}, {'type': 'standardizedContributor', 'first_name': 'Rogier', 'last_name': 'Buijsman', 'name': None, 'headline': 'Managing Director at NTRC Therapeutics BV'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}]}, {'name': 'A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.', 'publisher': 'British Journal of Pharmacology', 'url': 'http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.01859.x/pdf', 'date': {'month': None, 'day': None, 'year': 2012}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}, {'type': 'standardizedContributor', 'first_name': 'Folkert', 'last_name': 'Verkaar', 'name': None, 'headline': 'Associate Director at Charles River Laboratories'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'Husam Alwan', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Jos', 'last_name': 'de Man', 'name': None, 'headline': 'Senior Investigator at NTRC Therapeutics'}, {'type': 'standardizedContributor', 'first_name': 'Rogier', 'last_name': 'Buijsman', 'name': None, 'headline': 'Managing Director at NTRC Therapeutics BV'}]}, {'name': 'A theoretical entropy score as a single value to express inhibitor selectivity.', 'publisher': 'BMC Bioinformatics', 'url': 'http://www.biomedcentral.com/1471-2105/12/94', 'date': {'month': None, 'day': None, 'year': 2011}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Guido', 'last_name': 'Zaman', 'name': None, 'headline': 'Managing Director & Founder at Oncolines B.V.'}]}, {'name': 'Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way', 'publisher': 'Journal of Biomolecular Screening', 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/21873591', 'date': {'month': None, 'day': None, 'year': 2011}, 'authors': [{'type': 'standardizedContributor', 'first_name': 'Joost', 'last_name': 'Uitdehaag', 'name': None, 'headline': 'Head of Biology'}, {'type': 'standardizedContributor', 'first_name': 'Rita', 'last_name': 'Azevedo', 'name': None, 'headline': 'Senior Program Manager at Lygature'}, {'type': 'standardizedContributor', 'first_name': 'CÃ©cile', 'last_name': 'van den Elzen-SÃ¼nnen', 'name': None, 'headline': ""Lecturer HAS green academy 's-Hertogenbosch""}, {'type': 'standardizedContributor', 'first_name': 'Antoon', 'last_name': 'van Doornmalen', 'name': None, 'headline': 'Retired Senior Scientist'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'N de Rouw', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Arthur', 'last_name': 'Oubrie', 'name': None, 'headline': 'Chief Scientific Officer at Lead Pharma'}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'M Ziebell', 'headline': None}, {'type': 'nonStandardizedContributor', 'first_name': None, 'last_name': None, 'name': 'E Nickbarg', 'headline': None}, {'type': 'standardizedContributor', 'first_name': 'Willem-Jan', 'last_name': 'Karstens', 'name': None, 'headline': 'Principal Scientist bij Byondis'}, {'type': 'standardizedContributor', 'first_name': 'Simone', 'last_name': 'Ruygrok', 'name': None, 'headline': 'In-House CRA III at PRA Health Sciences'}]}]",[],[],"[{'company': {'id': 80911896, 'name': 'NTRC Therapeutics B.V.', 'logo': 'https://media.licdn.com/dms/image/C4D0BAQEmmAe4SY3sWQ/company-logo_400_400/0/1639599438385?e=1700697600&v=beta&t=NJur2gfUApKit_8B1YMTEzo6iZ3PZ3qMIaYSVervv7o', 'url': 'https://www.linkedin.com/company/ntrctx/', 'employees': {'start': 11, 'end': 50}}, 'date': {'start': {'month': 6, 'day': None, 'year': 2023}, 'end': {'month': None, 'day': None, 'year': None}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 6, 'day': None, 'year': 2023}, 'end': {'month': None, 'day': None, 'year': None}}, 'company': 'NTRC Therapeutics B.V.', 'description': None, 'title': 'Head of Biology', 'employment_type': 'Full-time'}]}, {'company': {'id': 4000527, 'name': 'Acerta Pharma B.V. (A member of the AstraZeneca Group)', 'logo': 'https://media.licdn.com/dms/image/C560BAQGHAmti1vu_ZA/company-logo_400_400/0/1519904244375?e=1700697600&v=beta&t=EgVnmkjdwIWyWvU512xQNPEyft4Ac07sc0ukDBJl3lg', 'url': 'https://www.linkedin.com/company/acerta-pharma-bv/', 'employees': {'start': 51, 'end': 200}}, 'date': {'start': {'month': 11, 'day': None, 'year': 2021}, 'end': {'month': 6, 'day': None, 'year': 2023}}, 'profile_positions': [{'location': 'Oss, Noord-Brabant, Nederland', 'date': {'start': {'month': 8, 'day': None, 'year': 2022}, 'end': {'month': 6, 'day': None, 'year': 2023}}, 'company': 'Acerta Pharma B.V. (A member of the AstraZeneca Group)', 'description': None, 'title': 'Associate Director', 'employment_type': 'Full-time'}, {'location': 'Oss, North Brabant, Netherlands', 'date': {'start': {'month': 11, 'day': None, 'year': 2021}, 'end': {'month': 8, 'day': None, 'year': 2022}}, 'company': 'Acerta Pharma B.V. (A member of the AstraZeneca Group)', 'description': 'Assessing and validating new targets in the hematology oncology arena, and nurturing them into full projects.', 'title': 'Associate Principal Scientist', 'employment_type': 'Full-time'}]}, {'company': {'id': 14434959, 'name': 'LAVA Therapeutics N.V.', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQFiFUgG1Jae3A/company-logo_400_400/0/1604497764176?e=1700697600&v=beta&t=5B_0aAkYXlVBwdeyPH52TGbBLFcNeBYO3-90QGy45yk', 'url': 'https://www.linkedin.com/company/lavatherapeutics/', 'employees': {'start': 11, 'end': 50}}, 'date': {'start': {'month': 3, 'day': None, 'year': 2020}, 'end': {'month': 11, 'day': None, 'year': 2021}}, 'profile_positions': [{'location': 'Utrecht Area, Netherlands', 'date': {'start': {'month': 3, 'day': None, 'year': 2020}, 'end': {'month': 11, 'day': None, 'year': 2021}}, 'company': 'LAVA Therapeutics N.V.', 'description': ""Program lead on LAVA's solid cancer programs. I brought the LAVA-1207 project from discovery stage into clinical trials.  Also program manager of the LAVA-Janssen collaboration, during which the project achieved its first milestone ahead of schedule.  Helping to grow and shape the LAVA organization from preclinical into a clinical stage biotech with a Nasdaq listing."", 'title': 'Director Program Management', 'employment_type': 'Full-time'}]}, {'company': {'id': None, 'name': 'Netherlands Translational Research Center BV', 'logo': None, 'url': None, 'employees': {'start': None, 'end': None}}, 'date': {'start': {'month': 10, 'day': None, 'year': 2011}, 'end': {'month': 3, 'day': None, 'year': 2020}}, 'profile_positions': [{'location': 'Oss, the Netherlands', 'date': {'start': {'month': 10, 'day': None, 'year': 2011}, 'end': {'month': 3, 'day': None, 'year': 2020}}, 'company': 'Netherlands Translational Research Center BV', 'description': ""Founding member of NTRC. Responsible for biotechnology and bioinformatics of NTRC's service platforms.  Senior biologist on two small molecule discovery projects, transforming them into clinical candidates. Chief writer of publications on projects and platforms in scientific journals."", 'title': 'Senior Investigator', 'employment_type': None}]}, {'company': {'id': 1486, 'name': 'Merck Sharp & Dohme', 'logo': 'https://media.licdn.com/dms/image/D4E0BAQFlCZ01Dm-rvw/company-logo_400_400/0/1688564237290?e=1700697600&v=beta&t=_nPHfn3JQyhWKxdzRK6rysbLVUYDm-W5phzbQJ7FbXw', 'url': 'https://www.linkedin.com/company/merck/', 'employees': {'start': 10001, 'end': None}}, 'date': {'start': {'month': 1, 'day': None, 'year': 2009}, 'end': {'month': 10, 'day': None, 'year': 2011}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 1, 'day': None, 'year': 2009}, 'end': {'month': 10, 'day': None, 'year': 2011}}, 'company': 'Merck', 'description': 'With my group I searched for new inhibitory compounds by combining new insights into enzyme mechanism with novel assay technology and high-throughput screening', 'title': 'principal research scientist', 'employment_type': None}, {'location': None, 'date': {'start': {'month': 2, 'day': None, 'year': 2009}, 'end': {'month': None, 'day': None, 'year': 2011}}, 'company': 'Merck', 'description': 'Responsible for molecular pharmacology in self-steering hit finding teams in oncology and inflammation. worked on half a dozen projects that generated clinical candidates', 'title': 'molecular pharmacology lead for immunology and oncology discovery', 'employment_type': 'Full-time'}]}, {'company': {'id': 2368, 'name': 'Schering-Plough Research Institute', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQH8e7Se56iX5w/company-logo_400_400/0/1519856120438?e=1700697600&v=beta&t=5yhePzwqN9z1v2qAFHvBW_JeNYOiCI4JozS1arvW3Vs', 'url': 'https://www.linkedin.com/company/schering-plough-research-institute/', 'employees': {'start': 10001, 'end': None}}, 'date': {'start': {'month': 2, 'day': None, 'year': 2007}, 'end': {'month': 2, 'day': None, 'year': 2011}}, 'profile_positions': [{'location': 'Oss', 'date': {'start': {'month': 2, 'day': None, 'year': 2007}, 'end': {'month': 2, 'day': None, 'year': 2011}}, 'company': 'Schering-Plough Research Institute', 'description': 'In my group, we set-up biochemical and cellular assay workflows for hit identification and lead finding projects.', 'title': 'group leader high throughput screening and kinase discovery', 'employment_type': 'Full-time'}]}, {'company': {'id': 3605, 'name': 'Organon', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQENIGtF2TM8qA/company-logo_400_400/0/1621271422164?e=1700697600&v=beta&t=yvszLmZv-J5hNAecbLVu70PdvFl8Rc-132ocb8ZZ_kM', 'url': 'https://www.linkedin.com/company/organon/', 'employees': {'start': 10001, 'end': None}}, 'date': {'start': {'month': None, 'day': None, 'year': 2002}, 'end': {'month': 2, 'day': None, 'year': 2007}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': None, 'day': None, 'year': 2002}, 'end': {'month': 2, 'day': None, 'year': 2007}}, 'company': 'Organon', 'description': 'I established the protein crystallography facility at Organon Biosciences, later Schering-Plough Europe. With my group I crystallized many interesting drug targets bound to drug candidates', 'title': 'group leader biochemistry and structural biology', 'employment_type': 'Full-time'}]}, {'company': {'id': 4477, 'name': 'University of Oxford', 'logo': 'https://media.licdn.com/dms/image/C560BAQGwPZs3spXFqw/company-logo_400_400/0/1539693367639?e=1700697600&v=beta&t=fIuLWhoOjqusT3q-nMhbr76n-POJcsxAGZrC91Cq38M', 'url': 'https://www.linkedin.com/school/oxforduni/', 'employees': {'start': 10001, 'end': None}}, 'date': {'start': {'month': 9, 'day': None, 'year': 2000}, 'end': {'month': 9, 'day': None, 'year': 2002}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 9, 'day': None, 'year': 2000}, 'end': {'month': 9, 'day': None, 'year': 2002}}, 'company': 'University of Oxford', 'description': 'Cloned, expressed and purified proteins of the innate immune system and looked at their interactions with a host of biophysical techniques', 'title': 'post doc - long term EMBO fellow', 'employment_type': None}]}, {'company': {'id': None, 'name': 'Danisco, Arhus', 'logo': None, 'url': None, 'employees': {'start': None, 'end': None}}, 'date': {'start': {'month': 6, 'day': None, 'year': 2000}, 'end': {'month': 6, 'day': None, 'year': 2000}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 6, 'day': None, 'year': 2000}, 'end': {'month': 6, 'day': None, 'year': 2000}}, 'company': 'Danisco, Arhus', 'description': 'Studied how to improve amylases by rational protein engineering.', 'title': 'consultant', 'employment_type': None}]}, {'company': {'id': 3153, 'name': 'Hebrew University Jerusalem', 'logo': 'https://media.licdn.com/dms/image/C4E0BAQEj9V8AF7dbfw/company-logo_400_400/0/1519856029126?e=1700697600&v=beta&t=Mvxa_0ltKCovv12AMG3mz180v-qEWRXoHy87kGs-UU8', 'url': 'https://www.linkedin.com/school/hebrew-university/', 'employees': {'start': 5001, 'end': 10000}}, 'date': {'start': {'month': 11, 'day': None, 'year': 1997}, 'end': {'month': 12, 'day': None, 'year': 1997}}, 'profile_positions': [{'location': None, 'date': {'start': {'month': 11, 'day': None, 'year': 1997}, 'end': {'month': 12, 'day': None, 'year': 1997}}, 'company': 'The Hebrew University of Jerusalem', 'description': 'Computer simulations of reaction pathways through trajectory calculations.', 'title': 'short term EMBO fellow', 'employment_type': None}]}]","[{'date': {'start': {'month': 8, 'day': None, 'year': 2015}, 'end': {'month': None, 'day': None, 'year': None}}, 'role': 'Author', 'company': {'id': None, 'name': 'Nimisa Publishing House', 'logo': None, 'url': None}, 'cause': 'ARTS_AND_CULTURE', 'description': 'Author of the biomedical novel ""Vechten voor Eva"" about the arduous journey of a woman through the world of new cancer medicine in an attempt to save her friend.'}, {'date': {'start': {'month': 5, 'day': None, 'year': 2008}, 'end': {'month': 5, 'day': None, 'year': 2011}}, 'role': 'Chairman', 'company': {'id': None, 'name': 'Gemeenschappelijke Medezeggenschapsraad (GMR) OOG-scholen', 'logo': None, 'url': None}, 'cause': None, 'description': ""chairing a general board of school worker's councils (17 schools with more than 3000 pupils)""}]","['kinase inhibitor', 'Hematology', 'Target Validation', 'Project Management', 'Crispr', 'Biotechnologie', 'Farmaceutische industrie', 'Creatief schrijven', 'Oncologie', 'Structural Biology', 'Biochemistry', 'Stories', 'Drug Discovery', 'Protein Purification', 'Bioinformatics', 'X-ray crystallography', 'Cell Based Assays', 'In Vitro', 'Assay Development', 'Enzyme Kinetics']",,,
